Can Iodized Salt Provide Enough Iodine? (TRT Q&As)
Timeline
The member asks whether switching from non-iodized sea salt to iodized salt could provide enough iodine. The discussion explains that the amount obtained from salt may be relatively small compared with higher iodine requirements and emphasizes properly evaluating iodine status rather than assuming dietary salt will correct a deficiency.
The member notices small pieces of the vial’s rubber stopper after repeatedly inserting a drawing needle and worries about injecting them. Dr. O’Connor does not consider it a major concern in this case, while the discussion also touches on proper vial handling and avoiding unnecessary contamination.
The member asks what health markers or milestones Dr. O’Connor considers before adding a DHT-derived androgen to testosterone. Dr. O’Connor emphasizes that adding another androgen is not necessary for TRT, can worsen the ABCDs™, and introduces additional cardiovascular, prostate, sexual, and central nervous system risks that must be weighed carefully.
A 64-year-old lifelong natural bodybuilder describes beginning TRT and then adding a testosterone and Masteron blast despite having a coronary calcium score of 212 and a prior stent. Dr. O’Connor focuses less on whether the dose qualifies as “small” and more on the member’s established coronary disease and the additional cardiovascular risk of escalating androgen exposure.
Dr. O’Connor describes becoming emotionally or sexually “flat” as a potential sign that the central nervous system is no longer responding to the drug in the same way. He discusses libido, erections, mood, anxiety, and other brain-related effects and cautions that DHT-derived steroids can affect individuals very differently.
Video Summary
This Ask The Doc live Q&A focuses on how clinicians approach testosterone therapy by integrating symptoms, laboratory trends, and overall health context. The discussion emphasizes why lab values alone rarely capture treatment success or failure. Energy levels, mood stability, sexual function, and physical performance are treated as interconnected clinical signals. The session highlights how individualized assessment replaces rigid protocol-based targets. Viewers gain insight into how clinicians manage variability between patients. Reassessment over time is emphasized rather than immediate correction. Education remains central to informed decision-making.
Safety and monitoring considerations are addressed throughout the conversation. Estradiol balance, hematocrit trends, and cardiometabolic risk awareness are discussed as ongoing responsibilities. The discussion explains why gradual adjustments are often safer than abrupt intervention. Baseline health factors such as body composition, insulin resistance, and cardiovascular history are incorporated into evaluation. Clinicians stress proportional responses to lab movement. Longitudinal trends are prioritized over single data points. This reflects contemporary standards of responsible hormone care.
Sexual health questions recur throughout the session, linking hormone balance with vascular and prostate health. Erectile dysfunction is discussed as a multifactorial issue rather than a single-hormone problem. Medication options are addressed within broader treatment planning. Prostate screening and urinary symptoms are framed through informed risk assessment rather than fear-based messaging. Clear communication between patient and clinician is emphasized. Shared decision-making is reinforced. Personalization remains the guiding principle.
Drug Callouts
Condition Callouts
Key Takeaways
- Hormone therapy decisions rely on symptom patterns and longitudinal lab trends rather than single values.
- Estradiol balance can influence side effects and treatment tolerance.
- Hematocrit monitoring supports safer long-term testosterone therapy.
- Sexual health concerns often reflect overlapping hormonal and vascular factors.
- Personalized follow-up improves understanding and clinical outcomes.